The Association of Complements, TGF-β, and IL-6 with Disease Activity, Renal Damage, and Hematological Activity in Patients with Naïve SLE
Table 3
Association of complement and cytokine levels with renal damage and hematological activity.
A
B
Statistical significance
BUN level
5–20 mg/dL (n=21)
>20 mg/dL (n=9)
C3
27.04 ± 11.19
33.18 ± 16.39
ns
C4
15.00 (7.60–20.60)
16.10 (6.00–36.00)
ns
TGF-β
34.44 ± 6.67
36.79 ± 7.96
ns
IL-6
194.5 (94.42–242.9)
358.5 (79.20–585.6)
ns
Creatinin level
≤1.2 mg/dL (n=21)
>1.2 mg/dL (n=9)
C3
28.60 ± 12.41
29.56 ± 15.01
ns
C4
15.50 (7.6–20.9)
14.30 (6–25.6)
ns
TGF-β
33.48 ± 6.79
39.04 ± 6.241
IL-6
206.8 (94.42–300.5)
162.4 (79.20–585.6)
ns
Proteinuria
0 and +1 (n=17)
+2, +3, +4 (n=13)
C3
28.19 ± 12.45
29.78 ± 14.11
ns
C4
13.90 (7–20.6)
15.80 (6.6–25.6)
ns
TGF-β
34.77 ± 7.12
35.64 ± 7.15
ns
IL-6
194.5 (120.4–300.5)
229.2 (79.20–536.0)
ns
Leukocyte count
≤11000 cells/ μ L (n=24)
>11000 cells/ μ L (n=6)
C3
31.91 ± 12.49
16.77 ± 6.287
C4
16.45 (10–24.4)
6.00 (5–15.5)
TGF-β
33.38 ± 6.326
42.22 ± 5.191
ns
IL-6
210 (94.42–358.5)
178 (16.19–860.5)
ns
Platelet count
150–400 × 10 9 /L (n=15)
150–400 × 10 9 /L (n=15)
C3
29.81 ± 13.96
27.96 ± 12.35
ns
C4
14.30 (7.00–25.60)
15.80 (7.00–20.90)
ns
TGF-β
37.06 ± 5.531
33.24 ± 7.982
ns
IL-6
168.5 (79.20–406.6)
213.8 (120.4–433.5)
ns
Hematocrit
35–25% (n=11)
<25% (n=19)
C3
28.73 ± 8.60
28.97 ± 15.18
ns
C4
16.10 (7.600–23.50)
14.30 (6.000–25.60)
ns
TGF-β
33.77 ± 6.608
35.94 ± 7.305
ns
IL-6
213.8 (94.42–406.6)
168.5 (75.03–517.7)
ns
ESR
≤29 mm/hour (n=7)
>29 mm/hour (n=23)
C3
33.53 ± 11.29)
27.47 ± 13.21
ns
C4
24.40 (6.60–34.20)
14.30 (7.60–18.00)
ns
TGF-β
37.19 ± 5.88
34.52 ± 7.34
ns
IL-6
89.57 (18.73–300.5)
213.8 (161.5–433.5)
C3, complement 3; C4, complement 4; TGF-β, transforming growth factor-beta; IL, interleukin; ESR, erythrocyte sedimentation rate; ns: no significance. Bold values indicated the grouping parameters of groups A and B.
